The elevated levels of interleukin-13 (IL-13) and the protein periostin seen in the whole blood samples taken from patients who had uncontrolled prurigo nodularis (PN) compared with a group of ...

One potential cause of the variability in response to treatment is heterogeneity in the role of interleukin-13 expression in the clinical asthma phenotype. We hypothesized that anti–interleukin ...

Significantly greater reductions in the mean esophageal eosinophil counts occurred in patients who received the humanized anti-interleukin 13 antibody, RPC4046. SEATTLE — RPC4046, a humanized ...

Ebglyss is a targeted interleukin-13 inhibitor approved for the treatment of moderate-to-severe atopic dermatitis. It can be used with or without topical corticosteroids. Eli Lilly and Company ...

SAN DIEGO, March 13, 2013 /PRNewswire/ – Receptos Inc. announced today that it has entered a Development License and Option Agreement to in-license a humanized anti-interleukin-13 (IL-13 ...

Dupilumab is a human monoclonal antibody that blocks interleukin-4 and interleukin-13 pathways and has shown efficacy in five different atopic diseases marked by type 2 inflammation, including ...

Researchers discovered an unexpected link between zinc deficiency, the pro-inflammatory cytokine interleukin-13 (IL-13), and Acinetobacter baumannii lung infection and demonstrated that blocking ...

Dupixent is a human monoclonal antibody specifically designed to inhibit signaling of interleukin-4 (IL-4) and interleukin-13 (IL-13), two important signaling proteins (cytokines) that contribute ...

SAN DIEGO, March 13, 2013 /PRNewswire/ -- Receptos Inc. announced today that it has entered a Development License and Option Agreement to in-license a humanized anti-interleukin-13 (IL-13 ...